TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03811327

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Zero-time Exercise
Description: A 2-hour group ZTEx training once per week for 2 consecutive weeks (totally 4 hours)
Study: NCT02129790

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mentalization-Based Therapy
Description: Up to 21 individual MBT-A sessions plus 9 monthly family sessions. MBT-A sessions will focus on the adolescent's recent social experiences and the resulting mental states and managing interpersonal challenges, particularly those involving separation or loss. The goal of this intervention is to improve the adolescent's ability to mentalize: to understand, acknowledge, and predict thoughts and feelings in oneself and others.
Study: NCT03129282

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-based Metacognitive Therapy (Home-MCT)
Description: Home-based metacognitive therapy (Home-MCT) is a facilitated self-help manual comprising six modules which participants will complete at their own pace over approximately 6 weeks. Participants will have an initial appointment with a Home-MCT trained cardiac rehabilitation staff members (face to face or by telephone). In addition, they will receive two telephone calls from trained cardiac rehabilitation staff members over the course of the intervention to offer support with completing the modules of the self-help manual.
Study: NCT03837964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1291583
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1291583
Description: Tablet
Study: NCT02975245

Intervention type: PROCEDURE
Intervention: Semen collection and analysis
Description: Semen sample will be collected prior to the initiation of chemotherapy and one week after the first round of chemotherapy.
Study: NCT01758978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: a 60 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 30-mg tablets (Treatment A) or one 60-mg tablet (Treatment B).
Description: Each subject will receive 1 treatment during each administration period. Subjects will receive each of the 2 treatments once. There will be a minimum 14-day washout period between the 2 administrations of study drug. Treatments will be orally administered to subjects, while they are seated, at approximately 0800 (±2 hours) on the 1st day of each administration period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: a 60 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 30-mg tablets (Treatment A) or one 60-mg tablet (Treatment B).
Description: Each subject will receive 1 treatment during each administration period. Subjects will receive each of the 2 treatments once. There will be a minimum 14-day washout period between the 2 administrations of study drug. Treatments will be orally administered to subjects, while they are seated, at approximately 0800 (±2 hours) on the 1st day of each administration period.
Study: NCT02521532

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary nitrate
Description: 140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
Study: NCT04264117

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FlexAbility (Mesh-like irrigated tip catheter) group
Description: 1. AF catheter ablation (PV isolation and linear ablations)~2. 30 sec ablation in each point~3. 35W in anterior LA, 30 W in posterior LA~4. Irrigation flow rate 13mL/min~5. Measuring procedure time, Ablation time~6. Rhythm follow-up based on guidelines

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TactiCath (Contract force monitoring catheter) group
Description: 1. AF catheter ablation (PV isolation and linear ablations)~2. contact force \>10g, target force-time integral 400 in each point~3. 35W in anterior LA, 30 W in posterior LA~4. Irrigation flow rate 15mL/min at 30W ablation, 30mL/min at 35W ablation~5. Measuring procedure time, Ablation time~6. Rhythm follow-up based on guidelines
Study: NCT02872857

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will match drug capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8mg galantamine twice daily
Description: Drug will be administered within 36 hours of hospitalization and continued for 90 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12mg galantamine twice daily
Description: Drug will be administered within 36 hours of hospitalization and continued for 90 days.
Study: NCT01848236

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D2
Description: Ergocalciferol vitamin D2

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Cholecalciferol vitamin D2
Study: NCT01825174

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ball games program
Description: twice a week different ball games 90min

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ball games program
Description: twice a week different ball games 90min

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ball games program
Description: twice a week different ball games 90min

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition counseling
Description: 9 units of 90min each of nutrition counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition counseling
Description: 9 units of 90min each of nutrition counseling
Study: NCT00460265

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARM 2
Description: Subjects will receive Cisplatin plus 5FU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARM 1
Description: Subjects will receive Panitumumab plus cisplatin and 5FU
Study: NCT01623973

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: specific training of paretic upper limb
Description: nineteen individuals with chronic stroke was randomly assigned, after the first evaluation, into two groups: group without restriction (G1), subject only to the specific training of paretic UL, and restricted group (G2), which underwent specific training of paretic UL and use of the restriction of non paretic UL. The volunteers were evaluated before the beginning of the interventions, and the next day after completion of the 12 therapy sessions through the Fugl-Meyer Assessment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: specific training of paretic upper limb
Description: nineteen individuals with chronic stroke was randomly assigned, after the first evaluation, into two groups: group without restriction (G1), subject only to the specific training of paretic UL, and restricted group (G2), which underwent specific training of paretic UL and use of the restriction of non paretic UL. The volunteers were evaluated before the beginning of the interventions, and the next day after completion of the 12 therapy sessions through the Fugl-Meyer Assessment
Study: NCT04544228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine + neostigmine
Description: 30 ml bupivacaine 0.25% + 1 ml neostigmine (500 μg)in Serratus Anterior Plane Block.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine +saline
Description: 30 ml bupivacaine 0.25% + 1 ml normal saline in Serratus Anterior Plane Block.
Study: NCT01376466

Intervention type: OTHER
Intervention: CT scanning
Description: CT image of the abdomen included the area between the 3rd. lumber vertebra and the top of acetabulum. A liter of contrast mixed with normal salin will be given by rectal catheter 20 minutes before CT image is taken.
Study: NCT02951910

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ophylosa tear supplement
Description: Tear film dynamics is assessed by non-invasive tear film breakup time (NI-BUT) in parallel with continuous recordings of ocular sensations during forced blinking. Corneal sensitivity thresholds to selective stimulation of corneal mechanonociceptors, thermal receptors and chemical nociceptors are assessed using the Belmonte gas esthesiometer. All baseline measurements are repeated after one month of tear supplementation with zinc-hyaluronate (Ophylosa eye drop) 4x/day
Study: NCT03434236

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low dose Lipinova (30 mL daily)
Description: Lipinova is a nutritional supplement containing concentrated n-3 PUFA (EPA and DHA) and metabolites

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will have a similar appearance, smell and taste as the nutritional supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high dose Lipinova (60mL)
Description: Lipinova is a nutritional supplement containing concentrated n-3 PUFA (EPA and DHA) and metabolites
Study: NCT02801474

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: direct fracture reduction and fixation
Description: In the DR group, the posterior malleolar fracture was reduced and fixed in a direct way via a posterolateral approach with the patients in prone position.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: indirect fracture reduction and fixation
Description: In the IR group, the posterior malleolus was reduced through ligamentotaxis following open reduction and internal fixation of lateral and medial malleolar fractures. Percutaneous cannulated screws were used to fix the posterior malleolar in anterior-to-posterior direction.
Study: NCT03452020

Intervention type: DEVICE
Group type: OTHER
Intervention: Temperature measurementsusing the Tyto thermometer, the standard of care thermometer and the predicate thermometer
Description: Temperature measurements using the Tyto thermometer, the standard of care thermometer and the predicate thermometer
Study: NCT00983489

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: video demonstration
Description: video will be shown to mothers

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: counselling
Description: breast feeding counselling
Study: NCT01941550

Intervention type: DRUG
Group type: OTHER
Intervention: Cabazitaxel chemotherapy
Description: given in 6 cycles
Study: NCT04360122

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levamisole
Description: Levamisole (150 mg/day for two days per week for 2 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoprinosine
Description: Isoprinosine (1 g 3 times per day daily) for two months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levamisole and Isoprinosine
Description: Levamisole (150 mg/day for two days per week for 2 months and Isoprinosine (1 g 3 times per day daily) for two months
Study: NCT04888702

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actimyo
Description: Actimyo° is an innovative device intended to be used in a home-based environment. It is composed of two watch-like sensors, each containing a magneto-inertial sensors that record the linear acceleration, the angular velocity, the magnetic field of the movement in all directions.The two watches can be worn as wristwatch or placed near the ankle.
Study: NCT01745315

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Advanced bipolar devices

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Advanced bipolar devices

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Advanced bipolar devices
Study: NCT04083963

Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: Low dose weekly carboplatin (AUC 2) will be combined with weekly paclitaxel for 12 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: Paclitaxel will be given weekly along with carboplatin for 12 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Doxorubicin
Description: Dose dense doxorubicin will be administered in combination with cyclophosphamide for 4 cycles after weekly carboplatin/paclitaxel.

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: Does dense cyclophosphamide will be in combination with doxorubicin for 4 cycles after weekly carboplatin/paclitaxel.
Study: NCT03414788

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF 06687234
Description: Subjects will be given single, intravenous dose of PF 06687234 and \[124I\]IB PF 06687234 simultaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: [124I]IB PF 06687234
Description: Subjects will be given single, intravenous dose of PF 06687234 and \[124I\]IB PF 06687234 simultaneously
Study: NCT03743363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exergame 2/week
Description: virtual training 2 times a week(8 week-long)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exergaming 3/week
Description: virtual training 3 times a week(8 week-long)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy control / Exergaming 1/week
Description: In the first 8 week-long only control group. For the next 8 weeks, the control group will do 1 workout per week.
Study: NCT01054872

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV-1 DNA plasmid vaccine
Description: 4 mg injection administered as 1 mL intramuscularly via Biojector in deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV-1 DNA plasmid vaccine
Description: 4 mg injection administered as 1 mL intramuscularly via Biojector in deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV-1 recombinant Ad5 vaccine
Description: 1 x 10\^10 particle units (PU) administered as 1 mL intramuscularly by needle and syringe in deltoid

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV-1 recombinant Ad5 vaccine
Description: 1 x 10\^10 particle units (PU) administered as 1 mL intramuscularly by needle and syringe in deltoid
Study: NCT00291655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: 500 mg oral tablets,1000 - 3000 mg/day, twice a day (BID), duration of the study
Study: NCT05480332

Intervention type: DEVICE
Intervention: EndoPAT
Description: We will use the standard non-invasive EndoPAT finger probes to conduct the studies. A single finger on each hand will be placed into a probe equipped with pressure sensors. A baseline recording period will be obtained. After five minutes, an occlusion phase will start where a blood pressure cuff on the patient's non-dominant arm will be inflated to 60mmHg above the patient's systolic pressure, or 200mmHg, whichever is higher. This phase will be conducted in concert with the standard instructions provided with the EndoPAT system. The occlusion phase will last for five minutes, after which time the cuff will be deflated. There will then be a five minute post-occlusion recording period. The test will then be completed.~The baseline period, occlusion period, and post-occlusion period will then be analyzed. A reactive hyperemia index score will be the desired output from the EndoPAT computer software, and will become the primary data point.
Study: NCT04328363

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Social prescription of health assets related to the practice of physical activity and a healthy eating pattern to modify lifestyles.
Study: NCT05689086

Intervention type: OTHER
Intervention: Virtual Heart Failure Optimization Program
Description: Participants referred to the Virtual Heart Failure Optimization Program will be seen for initial consultation by a HF program nurse and cardiologist within 1 week. Patients will be offered the opportunity to participate in virtual cardiac rehabilitation.~Following this, patients will be assessed virtually every two weeks by a HF program nurse for addition and up-titration of medical therapy. All medication changes will be performed algorithmically and reviewed with the overseeing cardiologist. Following all medication changes, appropriate monitoring will be performed algorithmically as well.~All participants will be asked if they would like to participate in cardiac rehabilitation and an automatic referral will be sent by the overseeing cardiologist. Virtual cardiac rehabilitation will be conducted weekly with phone follow-up appointments with a program kinesiologist and virtual education programming.
Study: NCT02952911

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone and Smartwatch
Description: Multiple sclerosis participants and healthy controls are required to wear the smartwatch; and to carry smartphone preferably in a median position in a belt bag, or alternatively in their pocket as they go about their daily routine.

Intervention type: DEVICE
Group type: OTHER
Intervention: Smartphone and Smartwatch
Description: Multiple sclerosis participants and healthy controls are required to wear the smartwatch; and to carry smartphone preferably in a median position in a belt bag, or alternatively in their pocket as they go about their daily routine.
Study: NCT03181126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: peg-asparaginase (or other form of asparaginase, per local standard of care (intravenous) + vincristine (intravenous) + dexamethasone (oral) + tyrosine kinase inhibitor (TKI) (if applicable, oral)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: tablet
Study: NCT01708889

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-914143 (Peginterferon Lambda-1a)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-914143 (Peginterferon Lambda-1a)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-914143 (Peginterferon Lambda-1a)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-914143 (Peginterferon Lambda-1a)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-914143 (Peginterferon Lambda-1a)
Study: NCT02352662

Intervention type: OTHER
Intervention: Perioperative blood samples collection
Description: Collect blood samples at 3 different points intra-operatively. Each blood sample will be run using rotational thromboelastometry to assess intraoperative coagulation
Study: NCT00289237

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Study: NCT04569968

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expiratory muscle training
Description: For training group first maximum expiratory pressure measurement will be assessed with portable expiratory measurement device. Measurement will be taken while the patient in a sitting position. Three measurement values with 5% variation will be taken an average of these values recorded as a maximum expiratory pressure of the patient. After the maximum expiratory pressure of the patient is measured 50% percent of the related value will be set on the expiratory muscle trainer. Then patient will be informed about how to use the trainer. Trainer will be used daily for four weeks with 50 repetitions. At the end of every week pressures will be measured again for re-calibration of the trainer.
Study: NCT02763332

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper trunk group (UTG)
Description: This bandage was placed over the upper trapezius muscle.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Global trunk group (GTG)
Description: This bandage was placed globally along the back
Study: NCT03357575

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells from adipose
Description: inject mesenchymal Stem Cells from adipose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid
Description: inject hyaluronic acid
Study: NCT03071731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bronchodilators
Description: Administration of a nebulized combination of bronchodilators before the administration of a functional test.
Study: NCT02300337

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reduce Cuff pressure
Description: We reduce the Cuff Pressure from the LTS-D (Laryngeal Tube suction) from 60 to 50 to 40 to 30cmH2O and measure the Delta from Inspiration to Expiration Tidalvolume (Delta Vt). The Delta Vt shows the actual leakage.
Study: NCT04691882

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diaphragmatic contraction
Description: Sequential periods (30 s) of voluntary diaphragmatic contraction after meal ingestion

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diaphagmatic relaxation
Description: Sequential periods (30 s) of voluntary diaphragmatic relaxation after meal ingestion
Study: NCT03963323

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucosamine Sulfate/Chondroitin Sulfate Tablet
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO
Study: NCT00505726

Intervention type: PROCEDURE
Intervention: Reflectance Confocal Imaging
Description: Microscopic images taken during routine colposcopy where disinfected probe inserted into vagina and placed against cervix, 1-3 regions imaged (2 abnormal and one normal), and each taking about 1-2 minutes.
Study: NCT03942783

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Published arthritis work booklets;written guidance on work problem identification; potential actions
Study: NCT00273351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [123I]B-CIT
Description: Subjects will receive up to 6 mCi of \[123I\] B-CIT injected intravenously
Study: NCT01802476

Intervention type: DRUG
Group type: OTHER
Intervention: Oral Drug Formulation of PD-0332991
Description: Treatment A consists of a single 125 mg oral dose of PD-0332991.
Study: NCT03488290

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LTP Plus TF-CBT
Description: Experimental: LTP Plus TF-CBT LTP Plus TF-CBT group participants will receive group intervention by masters' level trained facilitators weekly during the first two months and then fortnightly. It comprises of two components i.e. LTP and TF CBT. LTP aims at enabling parents to improve their child's psychosocial development by educating about child development and the importance of mother-child play. TF CBT aim is to modify excessively negative appraisals of the trauma and its sequelae by careful questioning

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: The Treatment as Usual group will receive routine care

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: The Treatment as Usual group will receive routine care